Jan Wehkamp, M.D., Ph.D. - VP Global Disease Area Lead Gastroenterology. Immunology Leadership Member - Janssen Pharmaceuticals J&J | LinkedIn
![PDF) Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies PDF) Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies](https://i1.rgstatic.net/publication/333445914_Efficacy_and_Safety_of_Adalimumab_by_Disease_Duration_Analysis_of_Pooled_Data_From_Crohn's_Disease_Studies/links/5cf1cd6c4585153c3daa27a3/largepreview.png)
PDF) Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies
Eric Mortensen en LinkedIn: Declining enrolment and other challenges in IBD clinical trials: Causes…
![T-knife Therapeutics bags $110M to sharpen solid tumor cell therapy push into the clinic | Fierce Biotech T-knife Therapeutics bags $110M to sharpen solid tumor cell therapy push into the clinic | Fierce Biotech](https://qtxasset.com/quartz/qcloud5/media/image/fiercebiotech/1627899641/Tom-Soloway_2-1.jpg?VersionId=k5zjWw0K3p0VabmFfw83Gv6yq9dcMvnJ)